Lakewood-Amedex Biotherapeutics, Inc. LABT PHARMA
Company Overview
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -97.48% |
| 6 Months: | - |
| 3 Months: | -65.94% |
| 1 Month: | -1.80% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)41.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 97.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LABT Lakewood-Amedex Biotherapeutics, Inc. PHARMA | 2.18 | -0.68 | $5.17M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 862.18K | 542.61K | 1.88M | 712.06K | 886.75K |
| Operating Income | -862.18K | -542.61K | -1.88M | -712.06K | -886.75K |
| EBITDA | -825.03K | -508.60K | -1.87M | -676.82K | -854.58K |
| Interest Expense | 0 | 1.31K | 37.81K | 37.81K | 38.22K |
| Pretax Income | -854.54K | -539.62K | -1.91M | -744.92K | -923.29K |
| Tax Provision | - | - | - | - | - |
| Net Income | -854.54K | -539.62K | -1.91M | -744.92K | -923.29K |
| Diluted EPS | - | -1.50 | -1.37 | - | -2.00 |
| R&D Expense | - | 169.70K | - | - | 182.15K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 8.64M | 4.03M | 3.77M |
| Operating Income | -8.64M | -4.03M | -3.77M |
| EBITDA | -8.15M | -4.73M | -3.63M |
| Interest Expense | 10.00K | 5.00K | 100.88K |
| Pretax Income | -8.28M | -4.86M | -3.85M |
| Tax Provision | - | - | - |
| Net Income | -8.28M | -4.86M | -3.85M |
| Diluted EPS | -11.84 | -6.94 | -2.76 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 6.89M | 1.07M | 481.60K |
| Current Assets | 6.48M | 773.98K | 305.39K |
| Cash & Equivalents | 2.53M | 681.10K | 236.40K |
| Inventory | - | - | - |
| Receivables | - | - | - |
| Total Liabilities | 2.34M | 660.97K | 2.45M |
| Current Liabilities | 2.06M | 500.63K | 2.41M |
| Long Term Debt | - | - | - |
| Total Debt | 578.88K | 272.86K | 1.66M |
| Total Equity | 4.56M | 409.61K | -1.96M |
| Shares Outstanding | 1.39M | 1.39M | 1.40M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -6.82M | -5.72M | -1.94M |
| Investing Cash Flow | -3.78M | 3.92M | 0 |
| Financing Cash Flow | 0 | -50.00K | 1.50M |
| Capital Expenditure | - | -1.85K | - |
| Free Cash Flow | -6.82M | -5.73M | -1.94M |
| Net Change in Cash | -10.60M | -1.85M | -444.70K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | -181.7% | -1,185.4% | 195.9% |
| ROCE % | -178.8% | -706.5% | 196.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Marex Group Ltd. | 2.03% | 48.17K | $95.85K |
| 2 | HRT Financial LP | 1.89% | 44.78K | $89.12K |
| 3 | UBS Group AG | 0.17% | 4.10K | $8.15K |
| 4 | Tower Research Capital LLC (TRC) | 0.03% | 624 | $1.24K |
| 5 | Osaic Holdings Inc. | 0.01% | 138 | $274 |
| 6 | Blue Trust, Inc. | - | 11 | $21 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LABT
Investors and potential partners will meet a biotech CEO from Lakewood-Amedex Sept. 14–16 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOaGgxYTc3aHdxeE00NmVOd25XRFpIVi03QTB2QWtEQW8zM3I0dzBSZnlwQ29mUmViekxsY1ZvX3FiNkdpWFppOVd6cnJBYWVMRk5ZaWFJLXdoOXhGcjJiNVUtWE9iOWJIYnpKWFprNHpvOGlmdldJeUtReUwyaTduWkRaSGxONk1SRWRMan…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1YNlZSbHJvek1XaXZCSmx0TkJiXzFHMTZtODZ0VVFZcmtQdEVuRGl5c3NDUjU2cXRiekRZV3lTcnl1NEUwSjlQT1BaVFM5Z2dk?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ: LABT) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTFBQVmhaaEs3TnVsN1ZPR2VZR0VyRWFnSzc1Rk56WG40NVA5QlZZWkRpTGNqc1drZnY1YkdVTnNDWi1HVURZNkF2aENJNjZFWWE3aWRkQ3Fn?oc=5" target="_blank">Lakewood-Amedex Biotherapeutics Inc. Common Stock (…
LABT Price Today: Lakewood-Amedex Biotherapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC
<a href="https://news.google.com/rss/articles/CBMiR0FVX3lxTE1VaFRZRTF5MGRiMVh6VGM4cmRXQmExMWw2eUNLU0NwRkdsTTEyekhIV2U0aUtiaUZSSklQdFNxc3FQS3JYNWxn?oc=5" target="_blank">LABT Price Today: Lakewood-Amedex Biotherapeutics Inc. Stock Price, Quo…
Lakewood-Amedex Biotherapeutics Surges as Fresh Nu-3 Data Draws Attention to Its Antibiotic-Resistance Program - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxNM1BGdzVvTEc2WnNoZ0tzNGtCc2RKRDhUS3hlYklKNmljdUhZUW1YRGJuenBmRFNNdEZiNzhUSWt6SjBmMml0MUp4dnVmbTdiSGI5dFI3d1c0MkI4NHRxazZ1LTAtMkduTjRvUXZtRURmVk5KMUVFRThmeEdIUU01UzZqTEZyc1RKT2Fzdl…
LABT Stock Whipsaws As Traders Eye Virtual Forum Exposure - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOaTI4aTg5cXJGQWt0Nl9lMWczTGRDYk9mNElvT1VTNWVOa0tlcjdRYi1tNldXTE5rNW9ob1NHRHUtV1EyQkZpXzZ6djlPTDdlUXFIZng5aHBrMWtzb2xzd0FQTS03ZDRhVTZKcGlUbWxJbVhfRkFTMGNVTjY4SnRCcDJvY2J5Ql9TTGQ4eW…
LABT — Frequently Asked Questions
What is the current share price of Lakewood-Amedex Biotherapeutics, Inc. (LABT)?
As of 2026-09-19 21:16 PDT, Lakewood-Amedex Biotherapeutics, Inc. (LABT) trades at $2.18 on NasdaqCM. Its 52-week range is $1.85 to $86.50.
What is the market capitalisation of LABT?
Lakewood-Amedex Biotherapeutics, Inc. (LABT) has a market capitalisation of $5.17M on NasdaqCM.
What is the P/E ratio of LABT?
LABT trades at a trailing price-to-earnings (P/E) ratio of -0.68. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.00.
Is LABT a good stock to buy?
This page provides a data-driven analysis of Lakewood-Amedex Biotherapeutics, Inc. (LABT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.